GSK pioneers new vaccine
NanoPass Technologies and GlaxoSmithKline's Biopharmaceutical Centre of Excellence for Drug Discovery have secured a grant from The Britech Foundation to optimise a new method of vaccine delivery.
MicroPyramid technology offers the possibility of effectively and painlessly administering vaccines intra-epidermally, something that conventional needles and other trans-dermal technologies are incapable of.
Shuki Yeshurun, the founder of NanoPass, said: 'there is potential that this technology may lower the amount of dose required to provide the same immune response, reduce the need for boosts, or potentially improve the protection rate by stimulating multiple immune pathways.'
NanoPass is an innovative medical device company working in the area of transdermal drug delivery. The company has several active collaborations underway in various application fields and is about to launch a new round of finance.
The Britech Foundation is a government-backed bilateral organisation providing active support for collaborative r&d ventures between UK and Israeli companies.
